AstraZeneca deepens cancer cell therapy portfolio with $320M Neogene buyoutBusiness, TherapeuticsAstraZeneca and Neogene have entered into a definitive acquisition agreement in which AstraZeneca will buy all outstanding equity in the smaller company for $320 million. Read more November 29, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/04/BioSpaceAstraZenecaflags4282022.jpg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-11-29 10:04:462022-11-29 13:04:39AstraZeneca deepens cancer cell therapy portfolio with $320M Neogene buyout
